Versus Systems Inc. (VS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. Versus Systems Inc. is a technology company providing proprietary gamification and prizing tools for sports franchises, streaming media, and live events. The company operates as a smaller reporting company and an emerging growth company. As of November 12, 2024, there were 2,746,505 common shares outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $3,848 | $22,950 | $57,288 | $236,953 |
| Net Loss | $(528,951) | $(1,535,787) | $(3,530,376) | $(5,019,067) |
| Operating Loss | $(529,024) | $(1,889,892) | $(3,530,128) | $(5,373,172) |
| Cash and Equivalents (End of Period) | $471,248 | $2,168,798 | $471,248 | $2,168,798 |
| Working Capital | $1,215,990 | $4,546,227 | $1,215,990 | $4,546,227 |
| EPS (Basic & Diluted) | $(0.22) | $(1.99) | $(1.29) | $(7.06) |
Liquidity: Cash decreased from $4.69 million at year-end 2023 to $471,248 at September 30, 2024. The company reported a net cash outflow from operating activities of $4.26 million for the nine months ended September 30, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 83% in Q3 2024 compared to Q3 2023, and 76% on a year-to-date basis. Management attributes this to a significant reduction in the number of active clients (from five at year-end 2023 to one at September 30, 2024) due to sales force reductions.
- Expense Reduction: Operating expenses decreased significantly due to restructuring. R&D expenses fell 96% in Q3, and SG&A expenses fell 68% in Q3, primarily driven by headcount reductions and lower professional fees.
- Loss Improvement: While the company remains unprofitable, the net loss narrowed by 65% in Q3 and 30% year-to-date compared to the prior year periods, reflecting the aggressive cost-cutting measures.
- Asset Base: Total assets decreased from $4.88 million to $1.24 million, driven by the burn of cash reserves and the write-down of intangible assets in the prior year.
Outlook, Risks, and Subsequent Events
- Going Concern: The filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern. The company has not achieved positive cash flow and relies on raising additional capital to fund operations.
- Nasdaq Compliance: The company received notice in August 2024 of non-compliance with the minimum stockholders' equity requirement ($2.5 million) and in September 2024 of non-compliance with the $1.00 minimum bid price requirement. Failure to regain compliance by March 16, 2025, could result in delisting.
- Subsequent Funding (ASPIS): In October 2024, the company entered a $2.5 million funding agreement with ASPIS Cyber Technologies. ASPIS delivered $500,000 initially, with $2.0 million deferred pending Nasdaq review. This funding is structured as a senior convertible promissory note.
- Technology License: Concurrent with the funding, the company signed a license agreement with ASPIS to use Versus technology in the cybersecurity sector, generating a potential monthly license fee of $165,000 starting January 2025.
- Warrant Exercise: In October 2024, warrant holders exercised 240,490 warrants, generating $885,003 in proceeds.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $471k cash balance plus the $500k ASPIS tranche to fund operations until the remaining $2M ASPIS funding is released or new capital is raised.
- Nasdaq Compliance Plan: Confirm the specific steps and timeline management intends to use to cure the stockholders' equity and minimum bid price deficiencies to avoid delisting.
- ASPIS Agreement Terms: Review the conversion terms of the convertible note and the conditions precedent for the release of the deferred $2.0 million funding.
- Customer Concentration: Assess the risk associated with having only one active customer as of September 30, 2024, and the viability of the new ASPIS partnership as a revenue replacement.
- Dilution Impact: Calculate the potential dilution from the conversion of the ASPIS note (approx. 2.15 million shares) and outstanding warrants (approx. 896,000 warrants).